Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 11Dermatologic 6Gynecologic 2Breast 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 27Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 13Melanoma 10Neoplasm Metastasis 9Colorectal Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Urogenital Neoplasms 4Multiple Myeloma 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Merkel Cell 3Prostatic Neoplasms 2Osteosarcoma 2Lymphoma 2Liver Neoplasms 2Kidney Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 9Cyclophosphamide 6fludarabine phosphate 4aldesleukin 3Radiotherapy 3Gemcitabine 3Drug Therapy 3Docetaxel 3Cetuximab 3temsirolimus 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2fludarabine 2entinostat 2durvalumab 2belinostat 2atezolizumab 2Sirolimus 2Paclitaxel 2Methods 2Metformin 2Irinotecan 2Interferon-alpha 2Bortezomib 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1tremelimumab 1tocilizumab 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × fludarabine × Breast × Clear all
NCT02111850 2022-03-29

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
21 enrolled 22 charts
BreastDermatologicGenitourinaryGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡